BUZZ-Wave Life Sciences rises after positive data on muscle disorder drug

Reuters03-26

** Drug developer Wave Life Sciences' WVE.O shares rise 16.1% to $10.96 premarket

** WVE says its experimental drug, WVE-N531, showed functional benefits and reversal of muscle damage in patients with Duchenne muscular dystrophy (DMD) in a mid-stage study

** Most DMD patients lack the protein dystrophin which keeps muscles intact

** Co intends to submit a marketing application to the FDA in 2026 for potential accelerated approval

** Co says 7 out of 8 patients "achieved greater than 5% average dystrophin between 24 and 48 weeks"

** Brokerage Truist Securities says the 48-week data is "impressive" for muscle damage reversal

** Up to last close, WVE has risen 63.3% in the past 12 months

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment